keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidemia, statins,

keyword
https://www.readbyqxmd.com/read/28095913/effects-of-a-purified-krill-oil-phospholipid-rich-in-long-chain-omega-3-fatty-acids-on-cardiovascular-disease-risk-factors-in-non-human-primates-with-naturally-occurring-diabetes-type-2-and-dyslipidemia
#1
Petter-Arnt Hals, Xiaoli Wang, Yong-Fu Xiao
BACKGROUND: High serum levels of cholesterol, in particular low-density lipoprotein cholesterol, are considered a significant risk factor for development of cardiovascular disease. Therefore, rigorous treatment regimens with statins and other pharmaceuticals have been used extensively to reduce elevated cholesterol levels. Literature data have not clearly concluded whether long-chain omega-3 fatty acids reduce, increase or leave circulating cholesterol unaffected. In the present study a novel krill-oil derived preparation of omega-3 rich phospholipids, mainly phosphatidylcholine, was administered orally at increasing doses for 12 weeks to dyslipidemic non-human primates, and cholesterols and several other risk factors for cardiovascular disease were measured before, during and after treatment...
January 17, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28093797/adverse-reactions-to-dietary-supplements-containing-red-yeast-rice-assessment-of-cases-from-the-italian-surveillance-system
#2
G Mazzanti, P A Moro, E Raschi, R Da Cas, F Menniti-Ippolito
BACKGROUND AND AIM: Red yeast rice (RYR) is contained in dietary supplements used in patients with dyslipidemia. RYR supplements contain monacolin K, which is chemically identical to lovastatin, a licensed drug with a well-known risk profile. We aimed to describe the safety profile of RYR by analysing spontaneous reports of suspected adverse reactions (ARs). METHODS: Within the Italian Surveillance System of Natural Health Products, suspected ARs were collected and evaluated by a multidisciplinary group of experts to assess causality using the WHO-UMC system or the CIOMS/RUCAM score, for hepatic reactions...
January 17, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28079508/management-of-dyslipidemia-in-high-risk-patients-with-recent-onset-rheumatoid-arthritis-targets-still-not-met-despite-specific-recommendations-results-from-the-espoir-cohort-during-the-first-five-years-of-follow-up
#3
Anne Tournadre, Bruno Pereira, Jean-Jacques Dubost, Nathalie Rincheval, Anne Christine Rat, Bernard Combe, Martin Soubrier
OBJECTIVES: Reduction of LDL-cholesterol (LDLc) is essential to decrease the cardiovascular mortality in rheumatoid arthritis (RA). Between 2005 and 2010, French recommendations for dyslipidaemia defined the LDLc target based on the number of cardiovascular risk factors. In 2006, it was recommended to consider LDLc objectives with RA being counted as an additional cardiovascular risk factor. Our objective was to assess lipid target achievement between 2006 and 2010 in a cohort of patients with recent-onset RA...
January 4, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28061854/association-of-statin-use-and-hypertriglyceridemia-with-diabetic-macular-edema-in-patients-with-type-2-diabetes-and-diabetic-retinopathy
#4
Yoo-Ri Chung, Sung Wook Park, Shin-Young Choi, Seung Woo Kim, Ka Young Moon, Jeong Hun Kim, Kihwang Lee
BACKGROUND: To investigate the effects of dyslipidemia and statin therapy on progression of diabetic retinopathy and diabetic macular edema in patients with type 2 diabetes. METHODS: The medical records of 110 patients with type 2 diabetes (70 statin users and 40 non-users) were retrospectively reviewed. The two outcome measures were progression of diabetic retinopathy by two or more steps on the early treatment diabetic retinopathy study scale and diabetic macular edema based on optical coherence tomography...
January 7, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28061433/lovastatin-upregulates-microrna-29b-to-reduce-oxidative-stress-in-rats-with-multiple-cardiovascular-risk-factors
#5
Fu Wang, Hui Ma, Wen-Jing Liang, Jing-Jing Yang, Xue-Qing Wang, Mei-Rong Shan, Yuan Chen, Min Jia, Ya-Ling Yin, Xue-Ying Sun, Jia-Ning Zhang, Qi-Sheng Peng, Yu-Guo Chen, Li-Ying Liu, Peng Li, Tao Guo, Shuang-Xi Wang
AIMS: Proteasome-linked oxidative stress is believed to cause endothelial dysfunction, an early event in cardiovascular diseases (CVD). Statin, as HMG-CoA reductase inhibitor, prevents endothelial dysfunction in CVD. However, the molecular mechanism of statin-mediated normalization of endothelial function is not completely elucidated. METHODS AND RESULTS: Lovastatin time/dose-dependently increased miR-29b expression and decreased proteasome activity in cultured human umbilical vein endothelial cells (HUVECs)...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28059952/atp-citrate-lyase-genetics-molecular-biology-and-therapeutic-target-for-dyslipidemia
#6
Amy C Burke, Murray W Huff
PURPOSE OF REVIEW: ATP-citrate lyase (ACLY) has re-emerged as a drug target for LDL cholesterol (LDL-C) lowering. We review ACLY as a therapeutic strategy, its genetics, its molecular and cellular biology, and also its inhibition. RECENT FINDINGS: ACLY is a critical enzyme linking glucose catabolism to lipogenesis by providing acetyl-CoA from mitochondrial citrate for fatty acid and cholesterol biosynthesis. Human genetic variants have been associated with enhanced growth and survival of several cancers, and with attenuated plasma triglyceride responses to dietary fish oil...
January 5, 2017: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/28058034/retrospective-analysis-of-the-effects-of-a-highly-standardized-mixture-of-berberis-aristata-silybum-marianum-and-monacolins-k-and-ka-in-patients-with-dyslipidemia
#7
Francesco Di Pierro, Pietro Putignano, Tarcisio Ferrara, Carmela Raiola, Giuliana Rapacioli, Nicola Villanova
BACKGROUND: Berberis aristata, because of its berberine content, and Monascus purpureus fermented rice, because of the presence of monacolins (naturally derived statins), are widely investigated food-grade ingredients used to formulate cholesterol-lowering supplements. Although they are extensively used, berberine is poorly absorbed and monacolins are poorly chemically characterized, not standardized, and possibly contaminated with toxic compounds. Silymarin is reported to enhance berberine absorption, while Monakopure™-K20 (MK-20) is a highly standardized red yeast rice containing monacolins K and KA in the ratio of 1:1 but not secondary monacolins, dehydromonacolins, or citrinin...
2017: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/28057504/prevalence-of-low-hdl-cholesterol-and-its-associations-among-sri-lankan-patients-with-diabetes-mellitus-on-statin-therapy
#8
Thilak Priyantha Weerarathna, Herath Mudiyanselage Meththananda Herath, Gayani Liyanage
AIMS: We aimed to study the prevalence and associations of suboptimal high density lipoproteins level, a characteristic feature in diabetic dyslipidemia among patients under statin therapy. MATERIALS AND METHODS: From a database of 2416 patients, data on age, gender, duration of diabetes, body mass index (BMI) and waist circumference (WC), low density lipoproteins (LDL), triglyceride, high density lipoproteins (HDL) were obtained. Prevalence of suboptimal HDL (<40mg/dL in males and <50mg/dL in females) and its association with gender, age, duration of diabetes, BMI and WC were studied...
December 26, 2016: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/28055995/-are-therapeutic-ldl-goals-justified-controversies-between-the-european-and-american-guidelines
#9
Vicente Bertomeu-Martínez
Dyslipidemia is one of the most important risk factors of the cardiovascular disease, so its treatment is one of the key strategies of cardiovascular prevention. Statins have been consolidated as the reference treatment for the reduction of serum cholesterol levels. There are some divergences in the treatment of dyslipidemia between American and European guidelines. This narrative review discusses the key points of this controversy.
December 30, 2016: Medwave
https://www.readbyqxmd.com/read/28052161/rate-of-statin-prescription-in-younger-patients-with-severe-dyslipidemia
#10
Sadeer G Al-Kindi, Anthony DeCicco, Chris T Longenecker, Jarrod Dalton, Daniel I Simon, David A Zidar
No abstract text is available yet for this article.
January 4, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28030716/association-of-fenofibrate-therapy-with-long-term-cardiovascular-risk-in-statin-treated-patients-with-type-2-diabetes
#11
Marshall B Elam, Henry N Ginsberg, Laura C Lovato, Marshall Corson, Joseph Largay, Lawrence A Leiter, Carlos Lopez, Patrick J O'Connor, Mary Ellen Sweeney, Daniel Weiss, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield, Richard Grimm, Faramarz Ismail-Beigi, David C Goff, Jerome L Fleg, Yves Rosenberg, Robert P Byington
Importance: Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk. Objective: To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes. Design, Setting, and Participants: Extended posttrial follow-up of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study participants between July 2009 and October 2014...
December 28, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/28029012/efficacy-of-moderate-intensity-statins-in-the-treatment-of-dyslipidemia-in-korean-patients-with-type-2-diabetes-mellitus
#12
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
BACKGROUND: There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM). METHODS: We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg)...
December 16, 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28003756/omega-3-carboxylic-acids-monotherapy-and-combination-with-statins-in-the-management-of-dyslipidemia
#13
REVIEW
Lane B Benes, Nikhil S Bassi, Michael H Davidson
The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management placed greater emphasis on statin therapy given the well-established benefits in primary and secondary prevention of cardiovascular disease. Residual risk may remain after statin initiation, in part because of triglyceride-rich lipoprotein cholesterol. Several large trials have failed to show benefit with non-statin cholesterol-lowering medications in the reduction of cardiovascular events. Yet, subgroup analyses showed a benefit in those with hypertriglyceridemia and lower high-density lipoprotein cholesterol level, a high-risk pattern of dyslipidemia...
2016: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/28000339/people-with-epilepsy-receive-more-statins-than-the-general-population-but-have-no-higher-cardiovascular-risk-results-from-a-cross-sectional-study
#14
R M Vivanco-Hidalgo, R Elosua, A Gómez González, A Moreira, L Díez, M Grau, I R Degano, J Roquer
BACKGROUND AND PURPOSE: Epilepsy has been associated with cardiovascular comorbidity. Risk prediction equations are the standard tools in primary prevention of cardiovascular disease. Our aim was to compare the prevalence of cardiovascular risk factors (CVRFs), cardiovascular risk and statin use in people with epilepsy (PWE) and the general population. METHODS: The CVRFs and cardiovascular risk score were compared between 815 PWE from an outpatient register and 5336 participants from a general population cohort...
February 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28000009/dyslipidemia-in-patients-with-chronic-kidney-disease
#15
REVIEW
Matthew R Hager, Archana D Narla, Lisa R Tannock
Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels...
December 20, 2016: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/27998714/a-nutraceutical-approach-armolipid-plus-to-reduce-total-and-ldl-cholesterol-in-individuals-with-mild-to-moderate-dyslipidemia-review-of-the-clinical-evidence
#16
Vivencio Barrios, Carlos Escobar, Arrigo Francesco Giuseppe Cicero, David Burke, Peter Fasching, Maciej Banach, Eric Bruckert
Compelling evidence supports the effectiveness of the reduction of total and LDL cholesterol (TC and LDL-C) in primarily preventing cardiovascular events, within the framework of life-long prevention programs mainly consisting in lifestyle changes. Pharmacological treatment should be introduced when lifestyle changes, including use of nutraceuticals, have failed. ESC/EAS guidelines list a number of nutraceutical compounds and functional foods which have been individually studied in randomized, controlled clinical trials (RCTs)...
February 2017: Atherosclerosis. Supplements
https://www.readbyqxmd.com/read/27993452/new-drugs-for-atherosclerosis
#17
REVIEW
Caroline S Bruikman, Robert M Stoekenbroek, G Kees Hovingh, John P Kastelein
Atherosclerosis, the underlying process that ultimately leads to clinical cardiovascular disease (CVD), is caused by the multifactorial interaction of various conditions, and dyslipidemia is widely acknowledged as 1 of the crucial risk factors in this process. Statin drugs have been shown to decrease low-density lipoprotein cholesterol and CVD morbidity as well as mortality and are therefore pivotal in CVD prevention. Despite the use of statin drugs, CVD remains a leading cause of mortality worldwide, which suggests that additional lipid-lowering therapies are warranted...
October 17, 2016: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/27988827/atherogenic-dyslipidemia-remission-1%C3%A2-year-after-bariatric-surgery
#18
Elisenda Climent, David Benaiges, Juan Pedro-Botet, Juana A Flores-Le Roux, Jose M Ramón, Montserrat Villatoro, Laia Fontané, Juan J Chillarón, Albert Goday
PURPOSE: Given the lack of evidence of the effect of bariatric surgery (BS) on atherogenic dyslipidemia (AD), which is a characteristic of obese subjects, this study aimed to describe the remission rate of AD 1 year after BS in severely obese patients. MATERIALS AND METHODS: A non-randomised, prospective cohort study was conducted in patients undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy with a 1-year follow-up. AD was defined as triglycerides ≥1...
December 17, 2016: Obesity Surgery
https://www.readbyqxmd.com/read/27960021/-dyslipidemia-in-kidney-transplant-recipients
#19
Giovanni Mosconi, Camilla Gambaretto, Loretta Zambianchi, Maria Francesca Lifrieri, Marco De Fabritiis, Stefania Cristino, Claudio Americo, Maria Laura Angelini
The kidney transplant recipients' population shows pronounced alterations of the lipidic profile, with hypercholesterolemia (total cholesterol, LDL, VLDL), normal HDL and hypertriglyceridemia. Multiple factors contribute to the development of dyslipidemia, towards these, immunosuppressive therapy plays an important role. The impact on cardiovascular outcomes is less well defined than in general population. This work is a revaluation of the clinical approach to dyslipidemia in kidney transplant based on the more recent Guide Lines and literature...
2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/27960010/-lipid-metabolism-abnormalities-in-chronic-kidney-disease
#20
Stefano Bianchi, Alessandro Baronti, Renato Cominotto, Roberto Bigazzi
Regardless of the etiology of renal disease, patients with chronic kidney disease (CKD) develop profound qualitative and quantitative lipoprotein metabolism abnormalities because of the presence of alterations in apolipoproteins, lipid transfer proteins, lipolytic enzymes, and lipoprotein receptors from the earlier stages of the disease. As renal function deteriorates, triglyceride concentrations increase and high-density lipoprotein cholesterol (HDL) concentrations decline, while levels of low- density lipoprotein (LDL) cholesterol remain in the normal range or become slightly decreased...
2016: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
keyword
keyword
118412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"